KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Operating Leases: 2019-2025

Historic Operating Leases for Nektar Therapeutics (NKTR) over the last 7 years, with Sep 2025 value amounting to $69.7 million.

  • Nektar Therapeutics' Operating Leases fell 19.62% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.7 million, marking a year-over-year decrease of 19.62%. This contributed to the annual value of $82.7 million for FY2024, which is 16.06% down from last year.
  • Per Nektar Therapeutics' latest filing, its Operating Leases stood at $69.7 million for Q3 2025, which was down 5.95% from $74.1 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Operating Leases registered a high of $134.6 million during Q1 2021, and its lowest value of $69.7 million during Q3 2025.
  • For the 3-year period, Nektar Therapeutics' Operating Leases averaged around $90.3 million, with its median value being $90.8 million (2024).
  • Data for Nektar Therapeutics' Operating Leases shows a maximum YoY fell of 19.62% (in 2025) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Operating Leases (Quarterly) stood at $125.7 million in 2021, then decreased by 10.27% to $112.8 million in 2022, then dropped by 12.68% to $98.5 million in 2023, then declined by 16.06% to $82.7 million in 2024, then declined by 19.62% to $69.7 million in 2025.
  • Its Operating Leases stands at $69.7 million for Q3 2025, versus $74.1 million for Q2 2025 and $78.5 million for Q1 2025.